Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Contact: Study coordinator (Feng Shi) · fengshihappy@126.com · +86 15989286619

Study leads

Xiaoming Chen
Principal Investigator
106 Second Zhongshan Road, Guangzhou, Guangdong

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma · Conversion Therapy

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular Carcinoma · Local Advanced Hepatocellular Carcinoma · Alpha-fetoprotein (AFP)-Producing Gastric Cancer

Abroad (travel likely)RecruitingPHASE1

Goodyear, United States · Duarte, United States

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases · Hepatocellular Carcinoma · Immunotherapy

Abroad (travel likely)Recruiting

Guanzhou, China